Introduction
The therapeutic index of the benzol hydrazone chlorhydrate of daunorubicin, RP 22050 (see fig.) , in the treatment of acute leukaemia is better than that of daunorubicin and its toxicity less than that of daunorubicin and of adriamycin (Skeel et al., 1970) . We report here a trial of RP 22050 in 44 RP 22050 was given by intravenous infusion in saline in a daily dose of 3-5 mg/kg until the total dose reached 20 mg/kg. Blood counts were made daily and bone marrow counts on the fifth, 10th, 15th, 20th, and 25th days. Aplasia of the bone marrow was usually noted after the 10th day, and if blast cells then persisted, even though white cells might be 1,000/mm3 or fewer, additional doses of RP 22050 3 mg/kg were given. One additional dose was given when blast cells were between 10% and 20%, two doses when they were between 20% and 50%, and three doses when they were more than 50%. Antibiotic treatment was essential during the aplastic phase in all patients. All patients also had platelet transfusions and 17 had transfusions of white cells from donors with chronic myeloid leukaemia. (Weil et al., 1972) whereas RP 22050 may be given over a longer period of time (Maral et al., 1972) , which allows the dose to be adjusted to each patient more easily. Regeneration is also progressive over two weeks or more, with a prolonged and moderate cytopenia.
Resistance occurs early with daunorubicin (Weil et al., 1972) (Bonadonna et al., 1969) showed that it has a higher therapeutic index than daunorubicin. We have given adriamycin in 16 cases of acute leukaemia-two in the first attack and 14 in relapse. The drug failed in the two patients in their first attacks. It induced two short remissions (one month and three months respectively) in three patients suffering their first relapse, but it failed in the other 11 patients in relapse. Four patients developed tachycardia and there was one case of cardiac failure.
Our experience of RP 22050 is therefore more encouraging. Its mode of action is probably near to that of daunorubicin and its haematological toxicity less pronounced. This suggests that RP 22050 should be considered as a drug for inducing remission in acute myeloid and other leukaemias. Its value compared to that of daunorubicin needs further investigation.
